2022 年 39 巻 3 号 p. 278-281
Quickly after its first report in Wuhan China in December 2019, Coronavirus Disease 2019 (COVID–19) has spread to the other parts of the world, and has led to the recognition of its pandemic by the Director–General of the World Health Organization on March 11, 2020. COVID–19 has imposed treamendous impacts on the clinical practice of chronic diseases including multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). Initially, clinicians and patients had to deal with the condition without knowledge on the novel virus, and therefore, several organizations have rapidly expressed recommendations for pateints and clinicians to follow. Thereafter, several registry–based studies have gradually figured out the effects of COVID–19 on MS and NMOSD, and have led to the repeated updates of the recommendations according to their results. In addition, information on the safety and effectiveness of COVID–19 vaccine in MS and NMOSD patients is accumulating after its launch in December 2020. This article summarizes the main findings in the research of COVID–19 and MS, NMOSD up to January 2022, and aim to help clinician to further collect information by themselves.
